An FDA advisory panel voted this week to add six peptides to the drug compounding list, including compounds like kisspeptin and thymosin beta-4. The panel rejected emideltide. HIMS stock rose as shares jumped overnight after the committee backed four peptides. Bachem's stock remained stable after the vote. A recent study indicated peptides may help treat antibiotic-resistant bacteria. Meanwhile, RFK Jr. advocated for easier access to controversial peptides, calling for slackened rules. The vote reflects a broader shift in how policymakers view compounded peptide therapies, which have drawn growing interest from users seeking alternatives to standard drugs. Researchers say peptide treatments could alter approaches to difficult infections, though concerns about quality persist. The committee's endorsement of six peptides clears a path for more broad prescribing, even as watchdogs warn of long-term evidence. Industry analysts note that peptide-focused companies may see greater investor attention following the panel's decision. The rejection of emideltide, meanwhile, underscores the FDA's cautious stance on some peptide candidates.